Frontiers of Oncology: Urology

This event is now closed, information is displayed here for information only.

The 2018 ‘Frontiers of Oncology: Urology’ meeting will be announced in Spring 2018

but you can pre-register HERE to be advised when the programme is released.

A one day meeting held on
Monday 19th September 2016
The Royal College of Physicians, London, UK

Frontiers of Oncology: Urology is a one day medical education meeting bringing together a notable faculty of Urology experts from UCL and beyond who will preview the latest advances in research, consider the likely impact on the clinic of tomorrow, and discuss and debate the pertinent issues which are affecting Urologists across the UK.


Mark Emberton
Professor Mark Emberton
Professor of Interventional Oncology
UCL Cancer Institute
Mark LinchDr Mark Linch
Medical Oncology Consultant
University College London Hospital

The full programme is here.

Who should attend?
This meeting is ideal for:

    • Consultants
    • GPs
    • Nurses
    • Researchers and
    • Scientists

and any healthcare professionals who have an interest in the future shape and direction of Urological research and treatment.

‘Frontiers of Oncology: Urology’ (code: 107238) has been approved for 4 category 1 credits (external) by the Federation of the Royal Colleges of Physicians of the United Kingdom.

When & Where
Monday 19th September 2016

The Royal College of Physicians, London, UK
11 St Andrews Place,
Map here

The meeting costs will be underwritten by Pharmaceutical Industry sponsors and the event is free of charge for healthcare professionals to attend. Places are strictly limited by room capacity.

This meeting is organised by:

New UCL Logo2 800



and endorsed and supported by:



Frontiers of Oncology meetings are supported by educational grants from the Pharmaceutical Industry.
As support agreements are reached, disclosure of the supporters is listed here.

The Frontiers of Oncology 2019 meetings are supported by the Pharmaceutical Industry.
As support agreements are reached, disclosure of the supporters is listed here.